Fundraising Fox
Autolus Therapeutics plc
NASDAQ: AUTLLondon · 2 known investors
Find your way into Autolus Therapeutics plc
Sign up to see every warm intro you have to Autolus Therapeutics plc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Autolus Therapeutics plc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
Founders & leadership
MP
Martin PuléSenior Vice President, Founder, Chief Scientific Officer
CW
Christopher WilliamsSenior Vice President, Chief Business Development Officer
RD
Robert DolskiSenior Vice President, Chief Financial Officer
CP
Cintia PiccinaUS General Manager and Chief Commercial OfficerChief Commercial Officer at Adaptimmune
AS
Alexander SwanSenior Vice President, Chief Human Resources Officer
Investors · 2
Reported raises · per SEC filings
Form D private placements$200M disclosed across 1 round · 2024
▶$200MraisedFeb 2024 · 1 investors · OtherRule 506(b)
▶$200MraisedFeb 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Christian ItinExecutive Officer, Director
- William D. YoungDirector
- Edgar BraendleExecutive Officer
- Martin MurphyDirector
- Linda BainDirector
- Christopher VannExecutive Officer
- Martin PuleExecutive Officer
- Cynthia ButittaDirector
- Robert AzelbyDirector
- David BrochuExecutive Officer
- Joseph AndersonDirector
- Robert IannoneDirector
- John BerrimanDirector
- John H. JohnsonDirector
- Elisabeth LeidermanDirector
- Brent RiceExecutive Officer
- Robert DolskiExecutive Officer
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Feb 2024
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Autolus Therapeutics plc do?
- Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
- Who founded Autolus Therapeutics plc?
- Autolus Therapeutics plc was founded by Martin Pulé, Christopher Williams.
- Who are Autolus Therapeutics plc's investors?
- Autolus Therapeutics plc's investors include Nextech Invest, Syncona.
- How much funding has Autolus Therapeutics plc raised?
- Autolus Therapeutics plc has disclosed $200M raised across 1 round.
- Where is Autolus Therapeutics plc headquartered?
- Autolus Therapeutics plc is headquartered in London.